Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Two parallel phase II randomized open label trials of Lutetium-177 Octreotate
(177Lu-Octreotate) peptide receptor radionuclide therapy (PRRT) and capecitabine
(CAP)/temozolomide (TEM) chemotherapy (chemo): (i) versus CAPTEM alone in the treatment of
low to intermediate grade pancreatic neuroendocrine tumours (pNETs); (ii) versus PRRT alone
in the treatment of low to intermediate grade mid gut neuroendocrine tumours (mNETs).